Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours-Reference-Cited by-同舟云学术

Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours

Published:2019 Issue:42 Volume:11 Page:20261-20273
ISSN:2040-3364
Container-title:Nanoscale
language:en
Short-container-title:Nanoscale

Author:

McDaid William J.¹²³⁴,Greene Michelle K.¹²³⁴,Johnston Michael C.¹²³⁴,Pollheimer Ellen¹²³⁴,Smyth Peter¹²³⁴,McLaughlin Kirsty¹²³⁴,Van Schaeybroeck Sandra¹²³⁴,Straubinger Robert M.⁵⁶⁷⁸⁹,Longley Daniel B.¹²³⁴,Scott Christopher J.¹²³⁴^ORCID

Affiliation:

1. Centre for Cancer Research and Cell Biology

2. Queen's University Belfast

3. Belfast

4. UK

5. Department of Pharmaceutical Sciences

6. University at Buffalo

7. State University of New York

8. Amherst

9. USA

Abstract

The use of CTX as a targeting agent for camptothecin-loaded polymeric nanoparticles directed against KRAS mutant CTX-resistant cancer cells was investigated. CTX increased CPT internalisation into cancer cells resulting in elevated cancer cell death.

Funder

Medical Research Council

National Institutes of Health

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science

Link

http://pubs.rsc.org/en/content/articlepdf/2019/NR/C9NR07257H

Reference42 articles.

1. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

2. Epidermal growth factor receptor (EGFR) signaling in cancer